Evaluation of Time in Therapeutic Range in Patients With Cerebrovascular Disease Receiving Treatment With Warfarin

dc.contributor.author Tamer, Pınar
dc.contributor.author İnci, İpek
dc.contributor.author Yılmaz Küsbeci, Özge
dc.contributor.author Ataç, Ceyla
dc.contributor.author Eşkut, Neslihan
dc.date.accessioned 2023-06-16T15:06:43Z
dc.date.available 2023-06-16T15:06:43Z
dc.date.issued 2021
dc.description.abstract Objective: The efficacy of warfarin therapy correlates with the Time in Therapeutic Range (TTR). This study aimed to investigate the efficacy and target achievement rates in patients using warfarin who were followed up in stroke outpatient clinics.Methods: In this study, 103 patients who had been under warfarin treatment were retrospectively evaluated. Duration and indications for warfarin use, thrombotic or hemorrhagic complications were recorded. Target INR value was 3.0-3.5 in patients with mechanical valves and 2.0-3.0 in those using warfarin for other indications.Results: In this study, 103 patients with a mean age of 67.14±14.19, 47 men and 56 women, were included. Indications for warfarin use, respectively, were non-valvular atrial fibrillation (AF) in 61.6% of the patients, akinetic/hypokinetic segment on echocardiography (ECHO) in 12.62%, thrombophilia in 8.74%, metallic prosthetic valve in 3.88%, frequent transient ischemic attacks in 6.79%, a hypokinetic segment on ECHO with atrial fibrillation in 5.82% and vertebral artery dissection in 0.87%. 46.8% of the patients were determined to be in good control, with a mean TTR of 64.09%; also, TTR was 100% in 36.8% of them. Minor/major hemorrhagic event was noted in 10 patients (9.70%), two of whom had an intracerebral hemorrhage.Conclusion: The mean TTR value detected in this study is considerably higher than the rate reported in our country. Findings of this study suggest that close monitoring is paramount of importance and vital in patients with stroke. Regular monitoring of stroke patients using warfarin will be beneficial in terms of informing patients, providing optimal anticoagulation and preventing complications. en_US
dc.identifier.doi 10.17944/mkutfd.937769
dc.identifier.issn 2149-3103
dc.identifier.uri https://doi.org/10.17944/mkutfd.937769
dc.identifier.uri https://search.trdizin.gov.tr/yayin/detay/440091
dc.identifier.uri https://hdl.handle.net/20.500.14365/4045
dc.language.iso en en_US
dc.relation.ispartof Mustafa Kemal Üniversitesi Tıp Dergisi en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Anticogulation en_US
dc.subject Efficacy en_US
dc.subject Warfarin en_US
dc.subject Ishemic Cerebrovascular Disease en_US
dc.title Evaluation of Time in Therapeutic Range in Patients With Cerebrovascular Disease Receiving Treatment With Warfarin en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.bip.impulseclass C5
gdc.bip.influenceclass C5
gdc.bip.popularityclass C5
gdc.coar.access open access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department İEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü en_US
gdc.description.departmenttemp Sağlık Bilimleri Üniversitesi, İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Nöroloji Anabilim Dalı, İzmir, Türkiye Sağlık Bilimleri Üniversitesi, İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Nöroloji Anabilim Dalı, İzmir, Türkiye İzmir Ekonomi Üniversitesi, Medical Park Hastanesi, Nöroloji Anabilim Dalı, İzmir, Türkiye Sağlık Bilimleri Üniversitesi, İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Nöroloji Anabilim Dalı, İzmir, Türkiye Sağlık Bilimleri Üniversitesi, İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Nöroloji Anabilim Dalı, İzmir, Türkiye en_US
gdc.description.endpage 93 en_US
gdc.description.issue 43 en_US
gdc.description.publicationcategory Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality N/A
gdc.description.startpage 88 en_US
gdc.description.volume 12 en_US
gdc.description.wosquality N/A
gdc.identifier.openalex W3193458519
gdc.identifier.trdizinid 440091
gdc.index.type TR-Dizin
gdc.oaire.accesstype GOLD
gdc.oaire.diamondjournal false
gdc.oaire.impulse 0.0
gdc.oaire.influence 2.4895952E-9
gdc.oaire.isgreen true
gdc.oaire.keywords Efficacy
gdc.oaire.keywords Anticogulation
gdc.oaire.keywords Ishemic Cerebrovascular Disease
gdc.oaire.keywords Warfarin
gdc.oaire.popularity 1.5483943E-9
gdc.oaire.publicfunded false
gdc.oaire.sciencefields 03 medical and health sciences
gdc.oaire.sciencefields 0302 clinical medicine
gdc.openalex.collaboration National
gdc.openalex.fwci 0.0
gdc.openalex.normalizedpercentile 0.18
gdc.opencitations.count 0
gdc.plumx.mendeley 1
gdc.virtual.author Yılmaz Küsbeci, Özge
relation.isAuthorOfPublication e0efe821-1393-4509-8dc3-5792d1287ced
relation.isAuthorOfPublication.latestForDiscovery e0efe821-1393-4509-8dc3-5792d1287ced
relation.isOrgUnitOfPublication 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd
relation.isOrgUnitOfPublication fbc53f3e-d1d3-4168-afd8-e42cd20bddd9
relation.isOrgUnitOfPublication e9e77e3e-bc94-40a7-9b24-b807b2cd0319
relation.isOrgUnitOfPublication.latestForDiscovery 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
3069.pdf
Size:
296.69 KB
Format:
Adobe Portable Document Format